Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this randomised, double-blind, placebo-controlled Phase II clinical trial is to
assess the safety and effect of of IHL-675A in rheumatoid arthritis patients on pain, and
function according to RAPID-3.
128 volunteers will be enrolled and randomised to one of four treatments (32 subjects per
treatment). Each treatment will be self-administered twice daily for 24 weeks.
The four treatments are:
- Treatment 1 - IHL-675A
- Treatment 2 - CBD
- Treatment 3 - HCQ
- Treatment 4 - Placebo